| 1.36 -0.03 (-2.16%) | 09-17 14:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.01  |
1-year : | 2.27 |
| Resists | First : | 1.72 |
Second : | 1.95 |
| Pivot price | 1.58 |
|||
| Supports | First : | 1.37 |
Second : | 1.13 |
| MAs | MA(5) : | 1.44 |
MA(20) : | 1.62 |
| MA(100) : | 2.23 |
MA(250) : | 3.28 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 1.9 |
D(3) : | 5 |
| RSI | RSI(14): 25.6 |
|||
| 52-week | High : | 7.07 | Low : | 1.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ORGO ] has closed above bottom band by 5.9%. Bollinger Bands are 3.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.47 - 1.48 | 1.48 - 1.49 |
| Low: | 1.36 - 1.37 | 1.37 - 1.38 |
| Close: | 1.37 - 1.39 | 1.39 - 1.41 |
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.
Thu, 20 Aug 2026
Spotlighting Anixa Biosciences And 2 Other Noteworthy Penny Stocks - simplywall.st
Fri, 07 Aug 2026
Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Thu, 06 Aug 2026
Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower - Investing.com
Thu, 09 Jul 2026
Organogenesis schedules Aug. 6 results call after market close - Stock Titan
Thu, 25 Jun 2026
ORGO Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 129 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 47.4 (%) |
| Held by Institutions | 51.8 (%) |
| Shares Short | 14,230 (K) |
| Shares Short P.Month | 13,130 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.14 |
| Profit Margin | -18.4 % |
| Operating Margin | -119.3 % |
| Return on Assets (ttm) | -4.2 % |
| Return on Equity (ttm) | -26 % |
| Qtrly Rev. Growth | -56.8 % |
| Gross Profit (p.s.) | 2.54 |
| Sales Per Share | 3.55 |
| EBITDA (p.s.) | -0.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 32 (M) |
| Levered Free Cash Flow | 28 (M) |
| PE Ratio | -1.75 |
| PEG Ratio | 0 |
| Price to Book value | 1.19 |
| Price to Sales | 0.38 |
| Price to Cash Flow | 5.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|